EUCTR2010-020603-79-SK进行中（未招募）1 期
A prospective, multicentre, randomised, double-blind, placebo-controlled, 3-parallel groups, phase 2 study to evaluate efficacy and safety of 12 weeks treatment with masitinib versus placebo in patients with acute ischemic stroke receiving stroke unit care with or without rt-PA therapy.
AB Science0 个研究点目标入组 48 人开始时间: 2016年1月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patient age 18 to 75 years old
- •2.Patient with a clinical diagnosis of acute stroke consistent with acute hemispheric cerebral infarction including hemiparesis and/ or hemiplegia involving the arm, leg, or both
- •3.Patient / representative able to understand the patient card and to follow the patient card procedures in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity.
- •4.Patient with symptom onset of = 12 hours before the start of treatment and symptoms present for = 1 hour
- •5.Patient with NIHSS score = 8 with at least 2 points from section 5 and 6 (motor)
- •6.Patient with pre-stroke Modified Ranking Scale < 1
- •7.Patient fully conscious
- •8.Patient functionally independent before the stroke (Barthel Index score = 100)
- •9.Patient weighing more than 50 kg and with a Body Mass Index (BMI) between 18 and 35 kg/m²
- •10.Patient with adequate organ functions defined as:
- •Absolute neutrophil count (ANC) = 2.0 x 109/L
- •Hemoglobin = 10g/dL
- •Platelets (PTL) = 100 x 109/L
- •AST/ALT = 3x ULN
- •Bilirubin = 1.5x ULN
- •Creatinin clearance > 60 mL/min (Cockcroft and Gault formula)
- •Albuminemia >1 x LLN
- •Proteinuria < 30 mg/dL (1+) on the dipstick. If proteinuria is = +1 on the dipstick, 24 hours proteinuria must be < 1.5g/24 hours.
- •11.twoFemale patient of childbearing potential
- •(entering the study after a menstrual period and who have a negative pregnancy test), who agrees to use two highly effective methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake
- •12.Male patients must use medically acceptable methods of contraception if his female partner is pregnant, from the time of the first administration of the study drug until three months following administration of the last dose of study drug. Male patients must use two highly effective methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake
- •13.Patient able and willing to comply with study procedures as per protocol
- •14.Patient or her/his representative able to understand, sign, and date the written informed consent form at baseline visit prior to any protocol-specific procedures
- •15.Patient affiliated to a social security regimen
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •1.Patient with a clinical diagnosis of acute stroke consistent with intracerebral hemorrhage
- •2.Patient inability to swallow study treatment tablets (tablets cannot be crushed, chewed or divided).
- •3.Patient with neurological sequellae from previous illness
- •4.Patient having cardiac disorders defined by at least one of the following conditions:
- •· Patient with recent cardiac history (within 6 months) of:
- •- Acute coronary syndrome
- •- Acute heart failure (class III or IV of the NYHA classification)
- •- Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular
- •fibrillation, resuscitated sudden death)
- •· Patient with cardiac failure class III or IV of the NYHA classification
- •· Patient with severe conduction disorders which are not prevented by permanent pacing (atrioventricular
- •block 2 and 3, sino-atrial block)
- •· Syncope without known aetiology within 3 months
- •· Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic
- •hypertension
- •5.Patient with severe concurrent illness and/or with life expectancy < 6 months
- •6.Patient with history of primary malignancy < 5 years, except treated basal cell skin cancer or cervical carcinoma in situ
- •7.Patient with a known diagnosis of human immunodeficiency virus (HIV) infection
- •8.Pregant or nursing female
- •9. Patient with history of poor compliance or history of drug/alcohol abuse, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent.
研究者
相似试验
进行中（未招募）
1 期
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)Patients with severe COPDEUCTR2012-005586-13-ESAB SCIENCE30
进行中（未招募）
不适用
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2010-021495-29-FRAB Science
进行中（未招募）
1 期
A study of a new iron medication for people with Crohn's Disease that is in remission and anaemia (low number of healthy red blood cells), who cannot use other oral iron medications either because they do not work, or because they cause side effects. (AEGIS 2)Iron deficiency anaemia in quiescent Crohn's DiseaseMedDRA version: 14.1 Level: PT Classification code 10022972 Term: Iron deficiency anaemia System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1 Level: LLT Classification code 10002062 Term: Anaemia iron deficiency System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-023589-39-GBIron Therapeutics (Switzerland) AG128
进行中（未招募）
1 期
clinical trial to assess efficacy and safety of masitinib in the treatment of Chronic Obstructive Pulmonary DiseaseSevere Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 20.0 Level: PT Classification code 10009033 Term: Chronic obstructive pulmonary disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-005586-13-SKAB Science45
进行中（未招募）
不适用
A study of a new iron medication for people with ulcerative colitis that is in remission and anaemia (low number of healthy red blood cells), who cannot use other oral iron medications either because they do not work, or because they cause side effects. (AEGIS 1)Iron deficiency anaemia in quiescent ulcerative colitisMedDRA version: 14.1Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-023588-16-HUIron Therapeutics (Switzerland) AG60